Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Consent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30,952 result(s) found for: Consent. Displaying page 1 of 1,548.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-000399-12 Sponsor Protocol Number: GPHIP_0202 Start Date*: 2021-04-16
    Sponsor Name:Grand Medical Pty Ltd
    Full Title: A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe COVID-19 Pneumonia
    Medical condition: severe pneumonia due to COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001346-17 Sponsor Protocol Number: ALN-GO1-005 Start Date*: 2020-02-20
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Completed) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Ongoing) Outside EU/EEA IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002620-17 Sponsor Protocol Number: 18-513 Start Date*: 2019-01-08
    Sponsor Name:Portola Pharmaceuticals, Inc
    Full Title: A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR
    Medical condition: Oral FXa inhibitor-treated patients with acute intracranial bleeding.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10075279 Anticoagulant reversal therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) NL (Completed) ES (Prematurely Ended) GR (Completed) CZ (Completed) LV (Completed) FI (Prematurely Ended) NO (Prematurely Ended) LT (Prematurely Ended) PL (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002011-61 Sponsor Protocol Number: 77267 Start Date*: 2021-08-13
    Sponsor Name:Academisch ziekenhuis Maastricht
    Full Title: The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome
    Medical condition: 22q11.2 deletion syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002747-29 Sponsor Protocol Number: BIA-2093-213 Start Date*: 2019-04-24
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate
    Medical condition: Adult patients at high-risk to develop post-stroke epilepsy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10076982 Post stroke epilepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003597-18 Sponsor Protocol Number: 18F-AV-45-010 Start Date*: 2009-05-28
    Sponsor Name:Avid Radiopharmaceuticals, Inc
    Full Title: A study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer's disease and normal controls
    Medical condition: Use of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10061816 Diagnostic procedure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002755-16 Sponsor Protocol Number: 23 Start Date*: 2007-11-07
    Sponsor Name:University Hospital Heidelberg
    Full Title: Pharmakokinetik von Posaconazol verabreicht über Magensonde - POLICE-Studie (POsaconazoLe via gastrIC tubE)
    Medical condition: All subjects are patients of a SICU. Apache Score > 30. Infection treatment or prophylaxis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000424-23 Sponsor Protocol Number: 331-13-211 Start Date*: 2014-10-31
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 2-month, Observational, Rollover Trial to Evaluate the Safety of Subjects with Agitation Associated with Dementia of the Alzheimer?s Type who were Previously Treated with Brexpiprazole (OPC-34712...
    Medical condition: Agitation Associated with Dementia of the Alzheimer's Type
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SI (Completed) FR (Completed) GB (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000175-33 Sponsor Protocol Number: D9484C00001 Start Date*: 2018-06-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy with Sodium Zirconium ...
    Medical condition: Heart Failure; Hyperkalaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000913-21 Sponsor Protocol Number: D1444C00147 Start Date*: 2004-10-05
    Sponsor Name:AstraZeneca R&D Södertälje
    Full Title: A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL) in P...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000369-44 Sponsor Protocol Number: 111375 Start Date*: 2009-03-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first v...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000396-26 Sponsor Protocol Number: EA-US-205-0111 Start Date*: 2015-02-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disea...
    Medical condition: Adult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003214-15 Sponsor Protocol Number: VP-AD-302 Start Date*: 2005-12-12
    Sponsor Name:Voyager Pharmaceutical Corporation
    Full Title: A DOUBLE-BLIND PLACEBO- CONTROLLED STUDY OF VP4896 FOR THE TREATMENT OF MILD-TO-MODERATE ALZHEIMER'S DISEASE
    Medical condition:
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) LT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005491-40 Sponsor Protocol Number: MRX-06-101-CP-01-01 Start Date*: 2007-07-10
    Sponsor Name:ImaRx Therapeutics, Inc
    Full Title: A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 with Continuous Ultrasound A...
    Medical condition: Acute Ischemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003678-22 Sponsor Protocol Number: APHP220257 Start Date*: 2023-02-27
    Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (APHP)
    Full Title: Impact of the increase in post-filter ionized calcemia target on the efficacy of regional citrate anticoagulation during continuous renal replacement therapy in intensive care: multicenter randomiz...
    Medical condition: Adult patients hospitalized in intensive care with an indication of RRT with ARC during the stay.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002513-27 Sponsor Protocol Number: 200862 Start Date*: 2014-11-19
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic...
    Medical condition: Subjects with severe asthma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) EE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001243-30 Sponsor Protocol Number: 840 30 40 Start Date*: 2004-12-09
    Sponsor Name:Apogepha Arzneimittel GmbH
    Full Title: Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinence. A randomised, double-blind, placebo-controlled, parallel grouped multicentre clinical trial.
    Medical condition: children suffering from overactive bladder and urinary incontinence
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) AT (Completed) SE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004049-29 Sponsor Protocol Number: ISSBRIL0264 Start Date*: 2015-03-10
    Sponsor Name:University of Leicester
    Full Title: Investigating Aspirin and Ticagrelor for the prevention of tumour cell-induced platelet aggregation
    Medical condition: Solid cancer metastasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002219-69 Sponsor Protocol Number: CHUBX2019/49 Start Date*: 2021-07-19
    Sponsor Name:CHU de Bordeaux
    Full Title: Long-term iron chelation in the prevention of secondary degeneration after cerebral infarction
    Medical condition: Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001759-42 Sponsor Protocol Number: 214094 Start Date*: 2020-05-20
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.
    Medical condition: Severe pulmonary COVID-19 related disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:14:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA